Georgia Urology physicians to treat more than 350 patients with the UroLift® System for enlarged prostate

ATLANTA, March 21, 2019 /PRNewswire/ -- Georgia Urology, the largest urology practice in Atlanta and throughout the Southeast, today announced that they will be surpassing the treatment of more than 350 patients with the UroLift^® System, a proven, minimally invasive technology to treat men suffering from symptoms associated with Benign Prostatic Hyperplasia, or BPH. Dr. Carl Capelouto reached his 100^th case in February, Dr. Ronald Anglade performs his 150^th case this month, and Dr. Lewis Kriteman will complete his 100^th procedure in April. These numbers make Georgia Urology the highest performing practitioners of the UroLift^® System in metro Atlanta.

"The UroLift^® System preserves sexual function which is important to men and their partners," says Dr. Ronald Anglade. "Patients like that they can have the treatment done in my office, in under an hour, with local anesthesia. And best of all, they experience rapid symptom relief and return to normal routines quickly," he adds.

Nearly 40 million men in the United States are affected by BPH. Not to be confused with prostate cancer, BPH occurs when the prostate gland that surrounds the male urethra becomes enlarged with advancing age and begins to obstruct the urinary system. Symptoms of BPH often include interrupted sleep and urinary problems, and can cause loss of productivity, depression and decreased quality of life. 

Five-year data from a randomized study shows the UroLift^® System offers not only rapid improvement, but also durable relief for patients with BPH. After five years, patients treated with the UroLift^® System continue to experience symptom relief with minimal side effects, with few patients requiring additional treatment for relief. A second randomized clinical trial called BPH6 demonstrated that the minimally invasive UroLift^® System compares very well to the reference standard surgery, transurethral resection of the prostate (TURP), with regard to efficacy, and is superior to TURP at preserving sexual function and offering a more rapid recovery. 

Medication is often the first-line therapy for enlarged prostate, but relief can be inadequate and temporary. Side effects of medication treatment can include sexual dysfunction, dizziness and headaches, prompting many patients to quit using the drugs. For these patients, the classic alternative is surgery that cuts, heats or removes prostate tissue to open the blocked urethra. While current surgical options can be very effective in relieving symptoms, they can also leave patients with permanent side effects such as urinary incontinence, erectile dysfunction and retrograde ejaculation.

Georgia Urology offers more than 30 locations in the Metro Atlanta area. Appointments can be made by calling 678-284-4053 or visiting gaurology.com/contact-us.

Interviews available upon request.

Georgia Urology is the largest urology practice in Atlanta and throughout the Southeast. Georgia Urology has more than 30 locations and six ambulatory surgery centers. The practice is comprised of more than 40 physicians, many of whom are fellowship-trained and hold advanced specialty training in oncology, robotic surgery, laparoscopy, infertility, incontinence, and pediatrics. Georgia Urology physicians use state-of-the-art diagnostic equipment and advanced treatment techniques, including robot-assisted technology and minimally-invasive procedures, in order to manage all urological problems in men, women, and children. It is the practice's mission to inform and partner with patients to develop a personalized, compassionate, and comprehensive treatment plan for all of their urological conditions.

About the UroLift^® System
NeoTract's FDA-cleared UroLift^® System is a proven, minimally invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia (BPH). The UroLift^® permanent implants, delivered during a minimally invasive transurethral outpatient procedure, relieve prostate obstruction and open the urethra directly without cutting, heating, or removing prostate tissue. Clinical data from a pivotal 206-patient randomized controlled study showed that patients with enlarged prostate receiving UroLift implants reported rapid and durable symptomatic and urinary flow rate improvement without compromising sexual function. Patients also experienced a significant improvement in quality of life. Most common adverse events reported include hematuria, dysuria, micturition urgency, pelvic pain, and urge incontinence. Most symptoms were mild to moderate in severity and resolved within two to four weeks after the treatment. The UroLift^® System is available in the U.S., Europe, Australia, Canada, Mexico and South Korea. Learn more at www.UroLift.com.  

Contact: Jon Waterhouse | Lenz, Inc.
404.373.2021
[email protected]

SOURCE Georgia Urology

Related Links

http://www.UroLift.com